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Abstract: The primary objective was to examine the role of pelvic fluid observed during transvaginal
ultrasonography (TVS) in identifying ovarian malignancy. A single-institution, observational study
was conducted within the University of Kentucky Ovarian Cancer Screening trial from January
1987 to September 2019. We analyzed true-positive (TP), false-positive (FP), true-negative (TN), and
false-negative (FN) groups for the presence of pelvic fluid during screening encounters. Measured
outcomes were the presence and duration of fluid over successive screening encounters. Of the
48,925 women surveyed, 2001 (4.1%) had pelvic fluid present during a TVS exam. The odds ratio
(OR) of detecting fluid in the comparison group (TN screen; OR = 1) significantly differed from that of
the FP cases (benign pathology; OR: 13.4; 95% confidence interval (CI): 9.1–19.8), the TP cases with a
low malignant potential (LMP; OR: 28; 95% CI: 26.5–29.5), TP ovarian cancer cases (OR: 50.4; 95% CI:
27.2–93.2), and FN ovarian cancer cases (OR: 59.3; 95% CI: 19.7–178.1). The mean duration that pelvic
fluid was present for women with TN screens was 2.2 ± 0.05 encounters, lasting 38.7 ± 1.3 months.
In an asymptomatic screening population, free fluid identified in TVS exams was more associated
with ovarian malignancy than in the control group or benign ovarian tumors. While pelvic free fluid
may not solely discriminate malignancy from non-malignancy, it appears to be clinically relevant and
warrants thoughtful consideration.
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1. Introduction
Ovarian cancer continues to be the most lethal gynecological cancer with most patients
facing a diagnosis of late stage metastatic disease that is associated with a five-year survival
of only 30%. While the lifetime risk of ovarian cancer is less than breast cancer, it has a
death-to-incidence ratio that is three to four times more than breast cancer [1–3]. Ovarian
cancer can arise from the ovary as well as the fallopian tube [4–11] and occur as five major
histological subtypes (high-grade serous, low-grade serous, endometrioid, clear cell, and
mucinous) that have been explored by immunochemical, genetic, and homologous recombination approaches [12]. Deleterious mutations in DNA repair genes can drive defective
homologous recombination and are emerging biomarkers of sensitivity/insensitivity to
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poly (ADP-ribose) polymerase (PARP) inhibitors which interfere with the ability of PARP
to repair treatment-mediated DNA damage in cancer cells [13]. Despite technically advanced treatment strategies in precision medicine and immunotherapy, long-term durable
treatment responses have not yet been achievable [14,15]. However, long-term survival
rates that are greater than 90% in women with stage I ovarian cancer have focused on an
advocacy for screening efforts to detect early-stage disease [16].
Transvaginal ultrasonography (TVS) is a safe, minimally invasive [17] and costeffective [18,19] modality that allows the visualization of echogenic structures and nonechogenic fluid. TVS has been used as a major modality in four major screening trials
for ovarian cancer including the Kentucky Ovarian Screening (KYOVS) trial [18,20], the
Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Randomized Controlled
Trial [21], the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) [22,23],
and the Shizuoka Cohort Study of Ovarian Cancer Screening (SCSOCS) trial [24]. The
reported findings from these studies are summarized in Table 1. Routine TVS can identify
free fluid in the abdomen or pelvis. Of the four major ovarian cancer screening trials that
utilized TVS, none examined the degree to which free fluid is associated with malignancy.
Consequently, there are no clear guidelines on the recommended management of free fluid
incidentally identified during a gynecologic ultrasound. Historically, physicians performed
culdocentesis to sample fluid in the pouch of Douglas [25], but this has been replaced by
ultrasound-guided paracentesis. Clinical guidelines are even less clear on how to manage
small-volume pelvic fluid collections.
Table 1. Summary of ovarian screening trials.
Study

KYOVS

PLCO

SCSOCS

UKCTOCS

Study design

Prospective
cohort (ongoing)

Intent to treat
RCT (closed)

Intent to treat
RCT (closed)

Intent to treat
RCT (closed)

Number screened

48,925 a

34,253 b
34,304 *

41,688 b
40,799 *

50,625 c
50,623 a
101,314 *

Total screens

326,998

150,598

156,747

345,570 c
327,775 a

Invasive ovarian
cancers detected

78

212 b

27

522 c
517 a
1016 *

Shift to early-stage
disease d

Yes (63%)

No

Yes (67%)

Yes (39.2%)

Survival benefit

Yes

No

No

No e

a US (transvaginal ultrasound) alone; b US alone followed by Ca125 and Ca125 alone; c Ca125 followed by US;
* control; d stages I and II; Randomized Control Trial (RCT); e Yes for incident cases, but under-powered.

In this report, we examined the frequency and duration of free fluid during TVS exams
in a large screening population and correlated the findings with the patient diagnosis.
Our primary objective was to determine if free fluid provides additional information in
predicting ovarian malignancy compared to ultrasound alone.
2. Materials and Methods
2.1. Subjects
Women enrolled in the KYOVS trial from January 1987 to September 2019 were
eligible for study inclusion. The University of Kentucky institutional review board for
human studies approved this prospective cohort trial (Transvaginal Ultrasonography as a
Screening Method for Ovarian Cancer, IRB #45030, renewed on 3 December 2021). Eligibility
criteria included asymptomatic women aged ≥50 years and asymptomatic women aged
≥25 years with a documented family history of ovarian cancer in at least one primary or
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secondary relative. Excluded from enrollment were women with a known ovarian tumor or
a personal medical history of ovarian cancer. All study patients provided written informed
consent before undergoing screening with transvaginal ultrasound. A board-certified
gynecologic oncologist reviewed all ultrasound images. The follow-up algorithm of normal
and abnormal scans has been previously published [18].
2.2. Interpretation of TVS Screening Results
Individuals were designated as a true-positive (TP), if they had histologically confirmed primary epithelial ovarian cancer, a low malignant potential ovarian tumor, a
non-epithelial ovarian malignancy, or metastatic disease to the ovary. A designation of a
true-negative (TN) screen was applied when a diagnosis of ovarian cancer did not occur
for at least 12 months after a “normal” TVS exam. False-positive (FP) screens included an
abnormal TVS screen found surgically to have benign ovarian histology, including serous
cystadenoma, endometrioma, mucinous cystadenoma, cystic teratoma, fibroma, thecoma,
Brenner tumor, leiomyoma, hydrosalpinx, paratubal cyst, and hemorrhagic cyst. We categorized study patients with a diagnosis of ovarian cancer occurring within 12 months of a
screening TVS exam that reported “normal” findings as a false-negative (FN).
2.3. Pelvic Free Fluid Identification
All sonographers in the University of Kentucky Ovarian Cancer Screening Program are
certified by the American Registry for Diagnostic Medical Sonography (ARDMS, Rockville,
MD, USA). We digitally recorded the findings of each ultrasound, including the presence
or absence of pelvic fluid, in case report forms maintained on a Medlog database (Medlog
Systems, Incline Village, NV, USA). We interpreted any amount of free fluid as a positive
finding, including the trace free fluid, small volume fluid (≤10 mL), and fluid collections
exceeding 10 mL. We determined the overall rate of free fluid identification as the ratio of
fluid positive cases to the total number of cases in individual categories.
2.4. Statistical Analysis
We compared demographic characteristics using X2 or Fisher’s exact test for categorical
data. We assessed continuous variables for normality and used non-paired t-tests or
Wilcoxon rank-sum tests as appropriate. For all analyses, we used a two-tailed test with
a significance level of p < 0.05. We used GraphPad Prism 5.01 (GraphPad Software, San
Diego, CA, USA) to perform the analyses.
We calculated the probability ratio (PR) for each group as the probability of an event
in one of the screening groups (TP, TN, FP, and FN). For example, the screening groups
consisted of women with fluid and without fluid relative to women with and without
fluid in the comparison group. The comparison group consisted of premenopausal normal
women (TN) with a body mass index (BMI) of <30. Pre- and post-menopausal women
with a BMI of ≥30 were found to have a lower PR of free fluid than those with a BMI
of <30; however, a very large body habitus can limit the detection of free fluid by TVS.
For this reason, we defined the comparison group as subjects with a BMI of <30. We
used VassarStat based on logistic regression to calculate PRs, odds, odds ratios (ORs), log
odds, Phi coefficients of association, association identified by X2 -square tests, Fisher’s exact
probability, and confidence intervals (CIs) [26].
2.5. Fluid Duration Analysis
The duration of free fluid was expressed both as the number of consecutive TVS exams
during which fluid was present and as a time duration during consecutive TVS exams.
3. Results
Since 1987, the University of Kentucky Ovarian Screening Program has performed
326,998 TVS screens on 48,925 women. We observed free fluid in 2001 (4.1%) of those
encounters. TP screens included 78 ovarian malignancies (13 fluid-positive, 16.7%), 20 tu-
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mors of a low malignant potential (two fluid-positive, 10%), and 23 malignancies of a
non-ovarian origin (three fluid-positive, 13%). Only one of the TP cases was observed
to have fluid present in a prior normal TVS exam. There were 614 FP screens classified
as high risk for ovarian cancer but found to have benign pathology (31 fluid-positive,
5%). Nine of these cases occurred in a prior normal TVS examination. The TN screens
included 41,996 cases that screened negative for malignancy and did not develop ovarian
carcinoma (1948 fluid-positive (4.6%): 1071 fluid-positive cases were associated with a
normal TVS examination, while 877 were associated with an abnormal TVS examination).
There were 21 cases of ovarian cancer diagnosed within 12 months of an FN TVS scan (four
fluid-positive, 19%). All of these cases occurred in the absence of an abnormal TVS exam.
3.1. Demographics
The demographic characteristics of the TN cohort demonstrated some significant
differences between fluid-positive and -negative subgroups. The fluid-negative subgroup
was older and had a higher parity and a higher BMI. They were also less likely to be
nulliparous or have a family history of ovarian or colon cancer. Although they were less
likely to have ever used hormone replacement therapy (HRT), more were using HRT at the
time of their last visits (Table 2).
Table 2. Demographic characteristics of true-negative (TN) screen subjects at the first ultrasound.
Demographic Variable

All TN Subjects
(n = 48,212)

TN and Fluid-Negative
(n = 46,263)

TN and Fluid-Positive
(n = 1949)

p

Age (y)

57.0, 57
(24–95)

57.3, 57
(24–95)

51.4, 52
(25–91)

<0.0001

Parity

2.3, 2
(0–19)

2.3, 2
(0–19)

2.1, 2
(0–8)

<0.0001

Weight (kg)

73.4, 70.3
(34–204)

73.5, 70.3
(34–204)

70.6, 67.1
(41–153)

<0.0001

Height (cm)

163.3, 162.6
(119–198)

163.3, 162.6
(119–198)

164.3, 165
(135–188)

<0.0001

11,329 (23.5%)
23,758 (49.6%)
13,433 (27.9%)

10,628 (23.0%)
22,797 (49.2%)
12,819 (27.7%)

701 (38.9%)
961 (49.3%)
614 (31.5%)

<0.0001
0.9790
0.0003

17,587 (36.5%)

16,711 (36.1%)

876 (44.9%)

<0.0001

5830 (12.1%)

5627 (12.2%)

203 (10.4%)

0.0205

7020 (14.6%)

6647 (14.4%)

373 (19.1%)

<0.0001

Family cancer history:
Ovary
Breast
Colon
No history of hormone
replacement therapy
Hormone replacement on the
last visit
Nulliparous

Data are represented as the mean, median, range within parenthesis, and percentage (%).

The fluid-positive and fluid-negative subgroups with a TP (Table 3) or FP screen
(Table 4) were similar, except for a higher parity in the FP fluid-negative group (p = 0.0344,
Table 4). We omitted the FN screen demographics because of the small sample size.
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Table 3. Demographic characteristics of true-positive (TP) screen subjects at the first ultrasound.
Demographic Variable

All TP Subjects
(n = 78)

TP and Fluid-Negative
(n = 64)

TP and Fluid-Positive
(n = 14)

p

Age (y)

65.5, 66
(36–86)

64.9, 66
(36–82)

68.4, 71
(45–85)

0.2285

Parity

2.0, 2
(0–8)

2.1, 2
(0–8)

1.8, 2
(0–5)

0.4818

Weight (kg)

71.4, 69
(44–122)

72.5, 69.7
(44–123)

67.7, 68.6
(52–82)

0.1920

Height (cm)

163.2, 163
(142–179)

163, 163
(152–178)

164.4, 165
(142–178)

0.4329

17 (21.7%)
33 (42.3%)
20 (25.6%)

15 (23.4%)
26 (40.6%)
16 (25%)

2 (14.2%)
7 (50%)
4 (28.6%)

0.7223
0.5614
0.7464

59 (75.6%)

48 (75%)

11 (78.6%)

1

6 (7.7%)

5 (7.8%)

1 (7.1%)

1

14 (17.0%)

9 (14.1%)

5 (35.7%)

0.1159

Family cancer history:
Ovary
Breast
Colon
No history of hormone
replacement therapy
Hormone replacement on the
last visit
Nulliparous

Data are represented as the mean, median within parenthesis, range, and percentage (%).

Table 4. Demographic characteristics of false-positive (FP) screen subjects at the first ultrasound.
Demographic Variable

All FP Subjects
(n = 614)

FP and Fluid-Negative
(n = 581)

FP and Fluid-Positive
(n = 33)

p

Age (y)

59.2, 59
(29–85)

59.3, 59
(29–85)

57.1, 59
(36–81)

0.2992

Parity

2.1, 2
(0–10)

2.1, 2
(0–10)

1.6, 2
(0–4)

0.0344

Weight (kg)

74.8, 72.6
(36–167)

75.1, 72.6
(36–167)

70.9, 69.9
(47–98)

0.1632

Height (cm)

164.4, 162.6
(139–181)

164.4, 162.6
(140–181)

164.8, 165
(152–175)

0.8202

Family cancer history:
Ovary
Breast
Colon

182 (29.6%)
269 (43.8%)
161 (6.2%)

168 (28.9%)
252 (43.3%)
148 (25.5%)

14 (42.4%)
17 (51.5%)
13 (39.4%)

0.0983
0.3592
0.0770

No history of hormone replacement therapy
Hormone replacement on last visit

60 (9.86%)
41 (6.7%)

58 (10%)
39 (6.7%)

2 (6.1%)
2 (6.1%)

0.7612
1

Nulliparous

31 (5%)

29 (5%)

2 (6.1%)

0.6797

Data are represented as the mean, median within parenthesis, range, and percentage (%).

3.2. Probability of Identifying Pelvic Fluid in Each Group
The PRs and the ORs were determined for women designated as TN for ovarian cancer
based on TVS findings. These women were then grouped on the basis of the menopausal
status, their BMI, and normal vs. abnormal TVS exams (Table 5).
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Table 5. Probability ratios (PRs) and odds ratios (ORs) of fluid observed by transvaginal ultrasonography (TVS) in women with TN results.
Group

Fluid-Positive

Fluid-Negative

PR (95% Confidence
Interval (CI))

OR (95% CI)

Premenopausal TN with fluid, a normal
exam and a BMI < 30

166

41,830

1

1

TN with fluid

1948

40,048

11.73
(10.02–13.74)

12.26
(10.45–14.37)

TN with fluid and a normal exam

1071

40,925

6.45
(5.48–7.59)

6.59
(5.60–7.77)

TN with fluid and an abnormal exam

877

41,119

5.28
(4.48–6.23)

5.37
(4.55–6.35)

Premenopausal TN with fluid and a
normal exam

207

41,789

1.25
(1.02–1.53)

1.25
(1.02–1.53)

Premenopausal TN with fluid, a normal
exam, a BMI ≥ 30

40

41,956

0.24
(0.17–0.34)

0.24
(0.17–0.34)

Premenopausal TN with fluid and an
abnormal exam

211

41,785

1.27
(1.04–1.56)

1.27
(1.04–1.56)

Premenopausal TN with fluid, an
abnormal exam, and a BMI < 30

158

41,838

0.95
(0.77–1.18)

0.0232
(0.77–1.18)

Premenopausal TN with fluid, an
abnormal exam, and a BMI ≥ 30

47

41,949

0.28
(0.20–0.39)

0.28
(0.20–0.39)

Postmenopausal TN with fluid and a
normal exam

862

41,134

5.19
(4.40–6.13)

5.28
(4.47–6.24)

Postmenopausal TN with fluid, a normal
exam, and a BMI < 30

675

41,321

4.07
(3.43–4.82)

4.12
(3.47–4.88)

Postmenopausal TN with fluid, a normal
exam, and a BMI ≥ 30

181

41,815

1.09
(0.88–1.35)

1.09
(0.88–1.35)

Postmenopausal TN with fluid and an
abnormal exam

666

41,330

4.01
(3.39–4.75)

4.06
(3.42–4.82)

Postmenopausal TN with fluid, an
abnormal exam, and a BMI < 30

512

41,484

3.08
(2.59–3.67)

3.11
(2.61–3.71)

Postmenopausal TN with fluid, an
abnormal exam, and a BMI ≥ 30

149

41,847

0.90
(0.72–1.12)

0.90
(0.72–1.12)

Note: 95% CIs are in brackets. Body Mass Index (BMI)

Using this categorical basis to normalize the PR and OR determination, we observed
that TN premenopausal women with a BMI ≥30 had the lowest PR and OR of fluid
observed during TVS exams. However, it was possible that a large body habitus might
have interfered with detecting fluid in these women during their TVS exams. This effect
would be least likely in TN premenopausal women with a BMI <30 that had received
a normal TVS exam, and we selected this group to normalize the PRs and the ORs. In
this analysis, the PRs ranged from 0.24 to 11.73, while the ORs ranged from 0.24 to 12.26
(Table 5), so that the entire ranges of the PRs and the ORs were defined for every TN
category. Next, we used the same approach to compare the PRs and the ORs for women
with positive TVS findings with regard to fluid status (Table 6).
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Table 6. PRs and ORs comparing fluid status in positive TVS findings.
Group

Fluid-Positive

Fluid-Negative

PR (95% CI)

OR (95% CI)

Table
6. PRs and ORsTN
comparing
Premenopausal
with fluid status in positive TVS findings.

Group
Premenopausal TN with
fluid, a normal exam, and a
BMI < 30
Benign findings (FPs)
Borderline tumor (low malignant potential (LMP))
Ovarian cancer (TP)
FN for ovarian cancer

fluid, a normal exam,
166
Fluid-Positive
Fluid-Negative
and a BMI < 30

166 findings (FPs)
Benign

41830

31

PR 41830
(95% CI)
1
614

12.16
26
(8.35–17.70)
18.07
26
(4.71–69.30)
13
78
36.14
78
(21.36–61.14)
FN for ovarian cancer
4
21
40.48
4
21
Note: 95% CIs are in brackets. Body Mass Index (BMI). (16.28–100.65)
Borderline tumor (low
31
malignant potential
(LMP))
2
Ovarian cancer (TP)
13

614

2

1 (95% CI)
OR
12.16 1
(8.35–17.70)

1

12.72
(8.60–18.82)

12.72
18.07
19.38
(8.60–18.82)
(4.71–69.30)
(4.56–82.33)
19.38
(4.56–82.33) 42.00
36.14
(21.36–61.14)
42.00 (22.90–77.03)
(22.90–77.03)
40.48
48.00
48.00 (16.30–141.35)
(16.28–100.65)
(16.30–141.35)

Note: 95% CIs are in brackets. Body Mass Index (BMI).

Findings associated with ovarian malignancy were statistically different from non-

Findings associated with ovarian malignancy were statistically different from nonmalignant cases (PR 36.14–40.48
= 36.14–40.48
vs. PRBenign
= 1–12.16; p < 0.001). There was no
malignant cases (PROvCa =OvCa
vs. PRBenign = 1–12.16;
p < 0.001). There was no statisstatistical
difference
in
the
detection
of
free
fluid
between
women
a low malignant
tical difference in the detection of free fluid between TP womenTP
with
a lowwith
malignant
potential
(LMP;
18.07;
95%4.71–69.3)
CI: 4.71–69.3)
TP women
withcancer
ovarian
potential
(LMP;
PR: PR:
18.07;
95% CI:
and TPand
women
with ovarian
(PR:cancer (PR:
36.14;
95%
21.36–61.14)
or women
with benign
(PR:
12.16;
95% CI: 8.35–17.7)
36.14;
95%
CI: CI:
21.36–61.14)
or women
with benign
findingsfindings
(PR: 12.16;
95%
CI: 8.35–17.7)
(Figure
(Figure
1). 1).

Figure 1. PR analysis of women with pelvic fluid present in TVS. PRs with 95% CIs are shown. TN and
benign findings vs. ovarian cancers (OvCa) were significantly different (p < 0.05). The classifications
of women who were TN for ovarian cancer were rank-ordered as identified by uppercase letters
within parentheses inside the figure.
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Figure 1. PR analysis of women with pelvic fluid present in TVS. PRs with 95% CIs are shown. TN
and benign findings vs. ovarian cancers (OvCa) were significantly different (p < 0.05). The classifications of women who were TN for ovarian cancer were rank-ordered as identified by uppercase
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letters within parentheses inside the figure.
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Thus,
our data
indicates
that free
fluid mostly disappears in non-malignant scenarios if serially monitored. Because of this
observation, it can be asked if fluid might be due to follicular fluid entering the peritoneal
cavity during ovulation. This possibility is unlikely, because premenopausal TN screens
were similarly low in the observation of fluid as postmenopausal cases (Figure 1 A–L). In
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addition, the six TP cases that were premenopausal at diagnosis were negative for fluid.
We recommend serial surveillance with TVS, until a malignant morphology is suspected
or the fluid resolves. Speculation on the source of fluid associated with malignant cases
could include the leakage of cyst fluid from ovarian cysts containing malignancy as an
explanation for fluid observed in the adnexa.
Only a few studies have reported the presence of pelvic fluid in investigations of
ovarian cancer. An underpowered study of 17 women evaluated an intra-ovarian blood
flow with 3-dimensional power Doppler ultrasound before surgical intervention in women
suspected of having ovarian carcinoma [37] and found no difference in pelvic fluid for
women with (16.7%) or without ovarian malignancy (18.2%; p = 0.938). Another study of
60 women with histologically confirmed primary peritoneal cancer investigated disseminated peritoneal carcinomatosis using TVS and documented the presence of free pelvic
fluid [38]. Given the advanced stage of disease at inclusion, it is not unexpected that the
study found 83% of women had free fluid present in the pelvic cul-de-sac. Lastly, investigators studied free pelvic fluid with magnetic resonance imaging (MRI) in women with
ovarian tumors. Eighty-seven women underwent surgery for pelvic tumors of unknown
malignant potential. Preoperative MRI indicated that the presence of large peritoneal fluid
pockets is moderately predictive of malignancy or peritoneal spread of the tumor [39].
Despite this, the recent American College of Radiology Ovarian-Adnexal Reporting and
Data System did not include fluid as a variable in the scoring algorithm for sonographically
indeterminate adnexal masses [40,41].
This study has several strengths. These data resulted from a substantial cohort of patients all screened in one program where operations and techniques were well standardized.
Throughout this study, the same Director of Research, Edward J. Pavlik (PhD) provided
consistent oversight and the same clinician, John R. VanNagell Jr., (MD) reviewed all TVS
scans. Lastly, it is relatively easy to identify free fluid on pelvic ultrasound because of the
inherent contrast between water-dense fluid and pelvic soft tissue.
There are also some study limitations. First, sonographers did not quantify the volume
of the pelvic free fluid on all studies. As a result, we included those with recorded fluid
volumes and test entries indicating fluid, possible fluid, ascites, and possible ascites. This
approach may have underestimated the number of subjects who had pelvic fluid present,
because it was not a required outcome measure. Since the peritoneal cavity contains
typically 50–75 mL of physiologic fluid that serves to lubricate the abdominal wall and
viscera [42–44], some fluid-positive cases may be a result of the pooling of this physiologic
fluid. In addition, because the views obtained in this screening study were limited to
the ovaries, it is possible that abdominal fluid above the pelvic brim or less likely fluid
in the pouch of Douglas may not have been observed, especially since the size of the
uterus varied in each individual [45]. Lastly, some demographic variables showed small
statistical differences between TN fluid-positive and -negative subgroups contributing to
potential bias.
5. Conclusions
Pelvic fluid identified during TVS screening is associated with ovarian malignancy
and should not be disregarded. The presence of free fluid during TVS should heighten
awareness for malignancy, particularly for an ovarian tumor with a high-risk morphology.
When free fluid associated with benign ovarian tumors is present for more than one
encounter, half of the cases resolve within 24 months. Since free fluid is associated with
ovarian malignancy, we recommend serial ultrasound surveillance, until a malignant
morphology is suspected or the fluid resolves.
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